Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis

Huiying Rao,xingxiang Yang,Youwen Tan,Qin Ning,Daokun Yang,Jie Fei Wang,Yongfeng Yang,Sujun Zheng,Dongliang Yang,Jinlin Hou,Qing Xie,Caiyan Zhao,Lunli Zhang,Xiaorong Mao,Tong Sun,Lang Bai,Fuchun Zhang,Jinglan Jin,Yingren Zhao,Maorong Wang,Wen Xie,Yingjie Ma,Jun. Quan,Xuebing Yan,Ping An,Feng Lin,Jidong Jia,Xiaoxuan Hu,Zuo-Jiong Gong,Jie Wu,Yongping Chen,Zhansheng Jia,Minghua Lin,Guiqiang Wang,Yueyong Zhu,Zhang Yingjun,Hongming Xie,Lin Luo,Ren Qingyun,Rui Huang,Lai Wei

Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis

2020

Background and Aims: Emitasvir is a new type of hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor, and the data of phase 2 trial has shown emitasvir-sofosbuvir to have good safety and tolerance. We conducted this phase 3 trial to further verify the efficacy and safety.

Keywords:

Cirrhosis
DIRECT ACTING ANTIVIRALS
Hepatitis C virus
Internal medicine
NS5A
Sofosbuvir
combined treatment
genotype 1b
Medicine
Gastroenterology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations